Multiple ascending-dose study of ICA 105665 at doses of up to 600mg in healthy volunteers.

Trial Profile

Multiple ascending-dose study of ICA 105665 at doses of up to 600mg in healthy volunteers.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2011

At a glance

  • Drugs ICA 105665 (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions
  • Sponsors Neusentis
  • Most Recent Events

    • 07 Mar 2011 Status changed from planning to completed.
    • 05 May 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top